70 results
PRE 14A
AXLA
Axcella Health Inc.
7 Aug 23
Preliminary proxy
4:15pm
held positions of increasing responsibility at Pfizer, with his last position as Vice President, heading up Pfizer’s Worldwide R&D Strategic … of increasing responsibility at MedImmune, LLC, a wholly owned subsidiary of AstraZeneca, most recently as Senior Vice President R&D, Head
DEF 14A
AXLA
Axcella Health Inc.
3 Apr 20
Definitive proxy
4:15pm
to this position, from March 2011 to September 2019, Dr. Rondinone served in roles of increasing responsibility at MedImmune, LLC, a wholly owned … served in increasing roles of responsibility at Novartis Pharmaceuticals Corporation, a pharmaceutical company, from December 2003 until November 2017
S-1/A
EX-10.10
6hwa zdme4fhdx2csr
30 Apr 19
IPO registration (amended)
6:06am
8-K
EX-99.1
6ebvei
7 Dec 21
Departure of Directors or Certain Officers
6:15am
8-K
tmt6x
7 Dec 21
Departure of Directors or Certain Officers
6:15am
S-1
EX-10.7
3eklt3ww5vbyi1ghffsg
12 Apr 19
IPO registration
7:02am
8-K
EX-99.1
eq2kis 0isya
3 Mar 21
Axcella Announces Alison D. Schecter, M.D., as President of R&D
5:26pm
8-K
EX-99.1
gmjt1 k687dcxeq
29 Jul 21
Axcella Reports Second Quarter Financial Results and Provides Business Update
7:58am
8-K
07zeg yiefohi0nvl
13 Oct 22
Entry into a Material Definitive Agreement
8:15am
S-3
EX-4.4
0g3 dv92abbd2w7
5 Jun 20
Shelf registration
5:02pm
S-3
EX-4.3
xf6lb6klm6
5 Jun 20
Shelf registration
5:02pm
S-1
EX-10.6
w877o3wvlj bfw7saec
12 Apr 19
IPO registration
7:02am
S-1
EX-10.5
3tftoe tvs
12 Apr 19
IPO registration
7:02am
S-1/A
EX-10.12
z5a0a4x9xuassb vjvor
30 Apr 19
IPO registration (amended)
6:06am